Sensipar Label Has Precautions On Hypocalcemia; Pre-Dialysis Indication Could Be Challenge
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen's chronic kidney disease treatment Sensipar includes precautions on hypocalcemia
You may also be interested in...
Amgen Will Not Pursue Sensipar Indication In Chronic Renal Insufficiency Patients
Phase III study of secondary hyperparathyroidism drug in patients with chronic renal insufficiency demonstrated incidences of hypocalcemia.
Amgen Will Not Pursue Sensipar Indication In Chronic Renal Insufficiency Patients
Phase III study of secondary hyperparathyroidism drug in patients with chronic renal insufficiency demonstrated incidences of hypocalcemia.
Amgen Sensipar Label Prepares For Off-Label Use In Pre-Dialysis Market
Review documents show that FDA crafted the calcimimetic's label with the expectation of off-label use in secondary hyperparathyroidism patients not yet on dialysis. Concern about Sensipar's potential to cause QT prolongation via hypocalcemia was a key factor in FDA's rejection of Amgen's request for approval in the pre-dialysis population.